生物技术公司AnaptysBio(ANAB)今日盘前大涨5%,引发市场广泛关注。根据路透社最新报道,虽然分析师下调了AnaptysBio的目标价,但大部分分析师仍然看好这家公司未来前景,予以"买入"评级。
具体来看,尽管分析师们普遍预计AnaptysBio即将公布的2024年第三季度财报将出现营收下降和亏损,但他们上调了对该公司的盈利预期,并给予较高的12个月目标股价中位数。这反映出分析师们对AnaptysBio长期增长潜力的信心。
华尔街分析师给予AnaptysBio的平均评级为"买入",12个月目标价中位数为48.5美元,较目前股价19.88美元有可观溢价。虽然公司短期业绩或将疲软,但分析师们似乎认为其核心竞争力和增长动力未受影响,预计未来表现向好。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.